 Dexanabinol is a synthetic cannabinoid which has previously undergone clinical trials for traumatic brain injury TBI and in subjects undergoing coronary artery bypass surgery. Currently dexanabinol is under investigation for potential anti-tumour activity in patients with advanced tumours. 